Being first to market has helped cement AstraZeneca PLC’s lead in the PARP inhibitor space with Lynparza (olaparib), now partnered with Merck & Co. Inc.Clovis Oncology Inc. is now first to the lucrative prostate cancer market with Rubraca (rucaparib), but Lynparza’s imminent approval and the difficulties of launching during a pandemic will make it difficult to capitalize on that advantage.
The US Food and Drug Administration granted accelerated approval for Rubraca on 15 May for treatment of adult patients with...







